Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:20:45 EDT Fri 18 Jul 2025
Enter Symbol
or Name
USA
CA



Q:IBIO - IBIO INC - https://www.ibioinc.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
IBIO - Q1.50.717·0.79320.10.731+0.0010.1682.14101,2480.7268  0.7334  0.71596.89  0.635819:36:59Jun 2415 min RT 2¢

Recent Trades - Last 10 of 1248
Time ETExPriceChangeVolume
19:36:59Q0.73 100
19:19:11Q0.73 100
18:48:27Q0.7181-0.011914
18:28:36Q0.73 15
16:48:40Q0.7299-0.00012
16:48:14Q0.7299-0.00011
16:39:11Q0.718-0.01224
16:19:09Q0.73070.0007500
16:19:09Q0.73080.0008500
16:09:29Q0.73070.00073

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-24 07:00U:IBIONews ReleaseiBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results
2025-06-23 16:15U:IBIONews ReleaseiBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call
2025-06-16 07:00U:IBIONews ReleaseiBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment
2025-05-05 08:00U:IBIONews ReleaseiBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model
2025-05-02 08:00U:IBIONews ReleaseiBio Reports Fiscal Third Quarter 2025 Financial Results
2025-04-29 13:44U:IBIONews ReleaseiBio Raises $6.2 Million Through Warrant Inducement Transaction
2025-04-22 08:00U:IBIONews ReleaseiBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio
2025-04-07 07:00U:IBIONews ReleaseiBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline
2025-02-19 16:05U:IBIONews ReleaseiBio to Begin Trading on the Nasdaq Stock Exchange
2025-02-10 16:05U:IBIONews ReleaseiBio Reports Fiscal Second Quarter 2025 Financial Results
2025-01-13 07:00U:IBIONews ReleaseiBio Announces New Investments from Board Members and Officers
2025-01-07 07:00U:IBIONews ReleaseiBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio
2025-01-02 07:00U:IBIONews ReleaseiBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio
2024-11-25 08:00U:IBIONews ReleaseiBio Strengthens Board with Appointment of Two New Independent Directors
2024-11-12 16:05U:IBIONews ReleaseiBio Reports Fiscal First Quarter 2025 Financial Results
2024-10-10 08:00U:IBIONews ReleaseiBio and AstralBio Provide Update on Myostatin Program for Obesity
2024-09-20 16:05U:IBIONews ReleaseiBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
2024-09-03 07:00U:IBIONews ReleaseiBio to Participate in Upcoming Investor Conferences
2024-08-12 16:30U:IBIONews ReleaseiBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development